Thuja Capital
Staf Van Reet, PhD, has a long track record in Pharma, among others as the Managing Director of Janssen Pharmaceutica N.V. and President of the Janssen Research Foundation, the worldwide research and development activities of the Janssen Group of companies. Additionally, Staf has solid experience in venture capital, having been responsible for corporate venturing in Europe as a Vice President of the Johnson & Johnson Development Corporation. Staf also gained extensive experience in the biotech sector as co-founder of Movetis and Chairman of its Board of Directors until the acquisition of the company by Shire. Currently, he is still active in various areas of the life sciences, among others as the founder and CEO of Viziphar Biosciences, as a Board member of Thrombogenics and Biocartis, and of the VIB, the Flemish Institute of Biotechnology.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Thuja Capital
Thuja Capital is an early-stage venture capital firm located in Utrecht, The Netherlands. They invest in product-focused companies that aim to have a true impact on patients and doctors alike, as demonstrated in clinical studies to enable a health claim.